The grant of these patents is likely to have a positive impact on BCLI's stock price in the short term as it solidifies the company's intellectual property and could provide a competitive edge in the market for neurodegenerative treatments. Patents are critical in the biotech industry for protecting R&D investments and maintaining exclusivity over novel treatments, which can lead to potential partnerships, licensing deals, or increased investor confidence.